Blog
RSS FeedPosted by Michael Wonder on 02 Dec 2016
NICE recommends new lung cancer drug pembrolizumab
2 December 2016 - Hundreds of people with advanced lung cancer will now have access to new drug pembrolizumab, also known ...
Posted by Michael Wonder on 01 Dec 2016
GSK gets green light to sell breakthrough asthma treatment to the NHS
1 December 2016 - GlaxoSmithKline has had one of its most promising new asthma drugs recommended for use on the ...
Posted by Michael Wonder on 30 Nov 2016
In the real world
30 November 2016 - The type of evidence NICE uses to make decisions is a hotly contested topic — and rightly ...
Posted by Michael Wonder on 30 Nov 2016
NICE says people with osteoporosis should be assessed for their fracture risk
30 November 2016 - People at risk of fractures due to osteoporosis should be considered for medication, NICE says. ...
Posted by Michael Wonder on 29 Nov 2016
NICE recommends 4p a day breast cancer drug
29 November 2016 - Women with a family history of breast cancer should be offered anastrozole, not tamoxifen, says NICE ...
Posted by Michael Wonder on 28 Nov 2016
Pfizer fears rough ride with NICE over breast cancer drug
28 November 2016 - Pfizer’s Ibrance breast cancer pill may have been a huge hit in the US, where it ...
Posted by Michael Wonder on 25 Nov 2016
NICE reverses decision on CDF leukaemia drug after price drop
25 November 2016 - Hundreds of people could benefit as NICE decision means ibrutinib can come off the Cancer Drugs Fund ...
Posted by Michael Wonder on 25 Nov 2016
Drug prices threaten the NHS
7 November 2016 - The recent Lancet Editorial on the High Court ruling that rejected NHS England's decision not to ...
Posted by Michael Wonder on 23 Nov 2016
NICE publishes final guidance on the use of nivolumab for RCC
23 November 2016 - NICE has published its third final appraisal determination for nivolumab for 2016. ...
Posted by Michael Wonder on 23 Nov 2016
NICE recommends extra ‘triple therapy’ drug for treating type 2 diabetes
23 November 2016 - NICE has published final guidance recommending dapagliflozin for treating type 2 diabetes in ‘triple therapy’. ...
Posted by Michael Wonder on 23 Nov 2016
NICE reviews multiple myeloma drug and approves for routine use
23 November 2016 - Hundreds of patients set to benefit after NICE draft guidance recommends pomalidomide, a drug that treats some ...
Posted by Michael Wonder on 19 Nov 2016
Will NICE "go commercial"?
17 November 2016 - NICE, like the NHS it supports, is looking at how to make big savings. One option ...
Posted by Michael Wonder on 17 Nov 2016
Price discount helps give green light for breast cancer drug pertuzumab
17 November 2016 - NICE approves the third breast cancer drug is as many weeks as pertuzumab is recommended to shrink ...
Posted by Michael Wonder on 17 Nov 2016
NICE approves three quarters of CDF group 1 drugs for routine use
17 November 2016 - More than 75% of treatments in the Cancer Drugs Fund which have been looked at again by ...
Posted by Michael Wonder on 15 Nov 2016
NICE says pancreatic cancer treatment considered not cost effective for routine NHS use
15 November 2016 - The drug pegylated liposomal irinotecan, was not clinically effective enough to justify its high cost, NICE says ...